Corixa Hands Over Bexxar® Rights to GSK
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 56 (Table of Contents)
Published: 5 Feb-2005
DOI: 10.3833/pdr.v2005.i56.726 ISSN: 1756-7874
Section: General
Abstract
Corixa completed the costly purchase of Coulter Pharmaceutical in order to acquire Bexxar® for the treatment of non-Hodgkin’s lymphoma, whereby it inherited GlaxoSmithKline (GSK) as a developer for antibody therapeutic...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
Last Issue PDF
RSS